课题基金 / 基金详情

Dissemination of Patient-Centered Outcomes Research in Hepatitis C Virus to Infec

Dissemination of Patient-Centered Outcomes Research in Hepatitis C Virus to Infec
传播以患者为中心的丙型肝炎病毒感染结果研究
批准号:
8810682
负责人:
David L Thomas
金额:
$9.21万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-04-01 至 2016-01-31

项目摘要

项目成果

David L Thomas的其他基金

相似基金

相关文献

中文摘要
翻译
背景:在美国,估计有近400万人感染丙型肝炎病毒(HCV),每年约有2万例新感染病例。卫生和公众服务部发布了一项预防、护理和治疗病毒性肝炎的行动计划,旨在提高对这一“无声的流行病”的认识,并减少丙肝病毒新感染病例的数量,所有这些都符合《健康人2020》的目标。最近对筛查成本效益的研究支持了一项主要回应,该研究促使疾病预防控制中心制定了新的HCV筛查指南,要求对1945-1965年出生的每个人进行筛查。这些新指南预计将于今年晚些时候发布,并将显著提高丙型肝炎病毒的识别。AHRQ编制了几份补充性综述,重点关注HCV筛查、治疗和治疗依从性。将这些信息迅速传播给识别专家是下一个关键步骤,但需要及时有效地提供资源。该方案提案的总体目标是通过扩大ID提供者识别和治疗HCV感染的能力来降低与HCV感染相关的发病率和死亡率。为了实现这一目标,IDSA的丙型肝炎工作组将开发17个教育项目和资源,以协助IDSA的专家和研究员进行病毒性肝炎的诊断、管理和治疗。具体而言,工作组将(1)以自我评估知识模块的形式对ID专家进行深度培训;(2)针对21种HCV的流行病学、诊断、管理和治疗,为ID研究员提供20个培训,显著扩大他们通过培训项目可获得的培训;22(3)向初级保健社区推广HCV筛查指南,23与诊断后的护理联系。24这一提议将直接支持实现《健康人2020》中与丙型肝炎病毒有关的两项目标25,即提高感染者认识的目标和减少新感染人数的目标26。鉴于HCV领域的快速变化的时机和IDSA通过教育活动(如本提案中计划的具体措施)影响其成员的28种实践模式的证明能力,成功的可能性很大。[1]李建平,李建平,李建平,李建平,李建平。美国丙型肝炎病毒感染的流行,1999年至2002年。Ann Intern Med 2006;144:705-14。二世疾控中心。急性病毒性肝炎的监测——美国,2008年。可在:http://www.cdc.gov/hepatitis/Statistics/2008Surveillance/index.htm。三、防治病毒性肝炎的无声流行:病毒性肝炎预防、护理和治疗行动计划。卫生与公众服务部2011年5月12日。2012年1月17日访问http://www.hhs.gov/ash/initiatives/hepatitis
英文摘要
DESCRIPTION (provided by applicant): 1 Dissemination of HCV Patient-Centered Outcomes Research - 2 Background: In the United States, nearly 4 million persons are estimated to be infected with 3 hepatitis C virus (HCV) with approximately 20,000 newly infected cases occurring each year.i,ii 4 Department of Health and Human Services has issued an action plan for the prevention, care 5 and treatment of viral hepatitis which aims to raise awareness of this "silent epidemic" and 6 reduce the number of new HCV infection cases, all in alignment with the Healthy People 2020 7 objectives.iii One major response is supported by recent research into the cost-effectiveness of 8 screening that has led the CDC to formulate new HCV screening guidelines that will call for the 9 testing of every person born 1945-1965. These new guidelines are expected to be released 10 later this year and will markedly increase HCV identification. 11 AHRQ has produced several complementary reviews focused on HCV screening, treatment, 12 and adherence to therapy. The rapid dissemination of this information to ID specialists is the 13 next critical step but requires resources to do so in a timely and effective manner. 14 The overarching goal of this program proposal is to reduce the morbidity and mortality 15 associated with HCV infection by expanding the capacity of ID providers to identify and treat 16 HCV infection. In order to achieve this goal, the IDSA's Hepatitis C Task Force will develop 17 educational programs and resources to assist ID specialists and fellows in the diagnosis, 18 management, and treatment of viral hepatitis. Specifically, the task force will (1) develop in- 19 depth training for ID specialists in the form of self-evaluation knowledge modules; (2) provide 20 training for ID fellows focused on the epidemiology, diagnosis, management, and treatment of 21 HCV, significantly expanding that which they may receive through their training programs; and 22 (3) provide outreach to the primary care community to promote HCV screening guidelines and 23 linkage to care following diagnosis. 24 This proposal will directly support the achievement of two of the Healthy People 2020 goals 25 related to hepatitis C virus - the goal of increasing the awareness of those infected and the goal 26 of decreasing the number of new infections. There is a high likelihood of success given the 27 timing of the rapid changes in the field of HCV and proven capability of IDSA to impact the 28 practice patterns of their membership through educational activities such as the specific 29 measures planned in this proposal. i Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-14. ii CDC. Surveillance for acute viral hepatitis-United States, 2008. Available at: http://www.cdc.gov/hepatitis/Statistics/2008Surveillance/index.htm. iii Combating the Silent Epidemic of Viral Hepatitis: Action Plan for Prevention, Care and Treatment of Viral Hepatitis. Department of Health & Human Services. May 12, 2011. Accessed on January, 17, 2012 at http://www.hhs.gov/ash/initiatives/hepatitis
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Interaction of Schistosomiasis mansoni and hepatitis B virus infections on hepatocellular carcinoma
  • 批准号:
    10259887
  • 项目类别:
  • 资助金额:
    $35.09万
  • 财政年份:
    2020
  • 负责人:
    David L Thomas
  • 依托单位:
Interaction of Schistosomiasis mansoni and hepatitis B virus infections on hepatocellular carcinoma
  • 批准号:
    10689175
  • 项目类别:
  • 资助金额:
    $35.13万
  • 财政年份:
    2020
  • 负责人:
    David L Thomas
  • 依托单位:
Interaction of Schistosomiasis mansoni and hepatitis B virus infections on hepatocellular carcinoma
  • 批准号:
    10471416
  • 项目类别:
  • 资助金额:
    $36.08万
  • 财政年份:
    2020
  • 负责人:
    David L Thomas
  • 依托单位:
Interaction of Schistosomiasis mansoni and hepatitis B virus infections on hepatocellular carcinoma
  • 批准号:
    10084616
  • 项目类别:
  • 资助金额:
    $28.27万
  • 财政年份:
    2020
  • 负责人:
    David L Thomas
  • 依托单位:
海外基金